Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1482–1486. doi: 10.1158/1078-0432.CCR-21-3074

Table 1.

Sotorasib Multiple-Dose PK Parameters on Day 8 Following Oral Administration of Various Dose Levels of Sotorasib QD under Fasted Conditions in Patients with KRAS G12C-Mutated Advanced Solid Tumors

Daily Dose (mg) N tmax (hr) Cmax (μg/mL) AUC0–24h (hr*μg/mL) t1/2,z (hr)
180 6 0.73 (0.50–1.2) 6.44 (7.63, 67%) 31.7 (40.8, 89%) 5.13 (1.99)
360 24 1.0 (0.50–4.0) 6.31 (7.33, 43%) 38.9 (43.7, 49%) 5.53 (1.84)
720 11 1.1 (0.53–4.0) 5.45 (6.76, 50%) 42.1 (48.5, 49%) 4.75 (1.16)
960 24 1.1 (0.22–6.5) 5.39 (6.82, 65%) 32.4 (42.3, 75%) 5.07 (1.08)

Data are presented as geometric mean (arithmetic mean, CV%) for all PK parameters except for tmax and t1/2,z, which is presented as median (range) and mean (SD).